NCT06779851 (SUMMIT-1) is a Phase 1 clinical trial of BPT567 in Advanced Solid Tumors, sponsored by Bright Peak Therapeutics Inc.

Who is sponsoring NCT06779851?

NCT06779851 is sponsored by Bright Peak Therapeutics Inc.

What drugs are being tested in NCT06779851?

Interventions in NCT06779851: BPT567.

What condition does NCT06779851 study?

NCT06779851 studies Advanced Solid Tumors.

Is NCT06779851 still recruiting?

NCT06779851 is currently active, enrolled. Last updated 13 February 2026.

Last reviewed 2026-02-13 · How we verify

NCT06779851: SUMMIT-1

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Evaluate Safety and Tolerability of BPT567 in Patients With Advanced Solid Tumors

Active, enrolled Phase 1 Last updated 13 February 2026

What this trial tests

Phase 1 trial testing BPT567 in Advanced Solid Tumors in 100 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

15 October 2024

Primary endpoint
31 December 2027

31 December 2028

Quick facts

Lead sponsor	Bright Peak Therapeutics Inc
Phase	Phase 1
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	100
Start date	15 October 2024
Primary completion	31 December 2027
Estimated completion	31 December 2028
Sites	7 locations across United States

Drugs / interventions tested

BPT567 — full drug profile →

Conditions studied

Advanced Solid Tumors — all drugs for Advanced Solid Tumors →

Sponsor

Bright Peak Therapeutics Inc — full company profile →

Who can join

18 and older, any sex, with Advanced Solid Tumors. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a first-in-human Phase Ia/Ib, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and maximum tolerated dose (MTD) or maximum adminstered dose (MAD) of BPT567 in patients with advanced solid tumors, and establish the recommended dose for expansion cohorts.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Advanced Solid Tumors

Currently open trials in the same condition.

NCT07504445 — Clinical Study on the Efficacy and Safety of CAR-DC in the Treatment of Advanced Solid Tumors · EARLY_PHASE1 · recruiting
NCT07589530 — Phase 1/2 Study of EB-NK-301 (Allogeneic TROP2-CAR NK Cells) in Advanced TROP2-Expressing Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07360314 — Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors · Phase 1 · recruiting
NCT07414316 — A Single-Arm, Open-Label Clinical Study GK01 Cell Injection in Subjects With Advanced Solid Tumors. · EARLY_PHASE1 · recruiting
NCT07222969 — A Clinical Study to Evaluate the Safety of VIB305 in Patients With Advanced Solid Tumors · Phase 1, PHASE2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06779851 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Bright Peak Therapeutics Inc
Last refreshed: 13 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06779851.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing